The FDA issued an emergency use authorization today for the Quidel Corp. (NSDW:QDEL) QuickVue At-Home COVID-19 test, another antigen test to rapidly collect and test samples at home, without needing to send a sample to a laboratory for analysis.
The QuickVue At-Home COVID-19 test is authorized for prescription home use with self-collected anterior nasal swabs from people ages 14 and older or children ages 8 and older with swabs collected by an adult. The test is authorized for those suspected of COVID-19 by their healthcare provider within the first six days of symptom onset.
“The FDA continues to prioritize the availability of more at-home testing options in response to the pandemic,” said Jeff Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health, said in a news release. “The QuickVue At-Home COVID-19 test is another example of the FDA working with test developers to bring important diagnostics to the public.”
In February…